Eloralintide
ENLIGHTEN-4
Eli Lilly · Phase 3 · Recruiting · Enrollment 900
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Eloralintide (YOA1) | n/r | n/r | n/r | n/r |
| Placebo (YOA1) | n/r | n/r | n/r | n/r |
| Eloralintide (YOA2) | n/r | n/r | n/r | n/r |
| Placebo (YOA2) | n/r | n/r | n/r | n/r |
Not shown
- Eloralintide (YOA1): endpoint not reported
- Placebo (YOA1): endpoint not reported
- Eloralintide (YOA2): endpoint not reported
- Placebo (YOA2): endpoint not reported